drugset

drugset / Trial / NCT00442104

Open-label Extension to Protocol 1042-0500

NCT00442104 ↗

Phase 2 Terminated 54 enrolled Marinus Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

To allow open-label extension to patients who have completed Protocol 1042-0500

Timeline

Start: 2007-01
Primary completion: 2009-03
Completion: 2009-03

Outcome

Outcome not reported

Stopped: “Sponsor's decision”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ganaxolone	Small molecule	—	—

Indications